Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

Abstract

Aim:We conducted a meta-analysis to evaluate the safety and efficacy of mirabegron (50 mg) and solifenacin (5 mg) monotherapy for overactive bladder (OAB) during a 12-week cycle. Methods: Randomized controlled trials (RCTs) of mirabegron and solifenacin for OAB were searched systematically by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of retrieved studies were also perused. Results: Five RCTs which compared solifenacin with mirabegron were studied.Mirabegron achieved the same effect as solifenacin in treating OAB. The mean number of incontinence episodes per 24 h (P = 0.20), mean number of micturitions per 24 h (P = 0.11), mean number of urgency episodes per 24 h (P = 0.23), and mean volume voided per micturition (P = 0.05) suggested that mirabegron and solifenacin had no significant differences in terms of OAB treatment. With regard to drug-related treatment-emergent adverse events (DR-TEAEs) and dry mouth, mirabegron showed better tolerance than solifenacin. Post-voiding residual volume showed a distinct difference in the two groups. Hypertension and tachycardia did not show a significant difference between the two groups, but the pulse rate did. Conclusion: The therapeutic effect of mirabegron is similar to that of solifenacin, and mirabegron does not increase the risk of adverse events (AEs). K E Y W O R D Smeta-analysis, mirabegron, overactive bladder, randomized controlled trials, solifenacin

Efficacy and Tolerability of Solifenacin Fumarate with Overactive Bladder Patients: A Multicenter Observational Study

“…The mean post-voiding residual volume was significantly higher in the solifenacin group. Similarly, dry mouth was higher in the solifenacin group, but the two groups did not differ significantly in terms of odd ratio for visual field abnormalities and constipation [13].…”

A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)

“…In one study comparing the efficacy of solifenacin and mirabegron in patients who were not satisfied with treatment due to lack of efficacy among patients taking anticholinergics except solifenacin, efficacy with mirabegron 50 mg was similar to solifenacin 5 mg. 20 A recent meta-analysis comparing the effects of mirabegron and solifenacin showed that the therapeutic effect of mirabegron is similar to that of solifenacin. 28 Considering these evidence, OAB patients who experienced poor efficacy with previous anticholinergic treatment benefitted from mirabegron and solifenacin. Our study differed from that of the previous studies.…”

RE: Meta‐analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder

“…For meta-analysis, the study could be defined as a fixed-effects model if P > .05, if not, a random-effects model would be chosen. 1 However, in fig. 2(D), the heterogeneity test showed P = .51 and a fixed-effects model should be chosen instead of random-effects model.…”